Related posts

Investing in Ozempic Stocks – Unlocking the Stock Price Growth PotentialBest Europe Stocks to Buy: Will 2020 See a European Renaissance?26 Stock Top Picks and 3 ETF (Dec 7-13)
Investor Insights

This summary was created by AI, based on 25 opinions in the last 12 months.

Experts have varying opinions on Novo-Nordisk (NVO-N) stock, with some highlighting the company's strong position in the obesity drug market and potential for future growth. Others caution about the rising competition and long-term effects of the weight-loss drugs. The stock's recent momentum and positive earnings are also noted, along with the company's dominance in diabetes care. Overall, the stock appears to have generated considerable interest and debate among experts due to its involvement in the weight-loss drug market, with both positive and cautious sentiments expressed.

Consensus
mixed
Valuation
Fair Value
Similar
Eli-Lilly, LLY
TOP PICK
Novo-Nordisk

High growth ahead. Europe's most valuable company by market cap. They lead the market in diabetes care, supplying half the world's insulin. Command one-third of the diabetes treatment business. Their weight-loss drug is growing strong which also prevents stroke and drives more demand. The chart is a dream. 18-20% EPS growth lies ahead.

(Analysts’ price target is $131.89)
biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

It has quality drugs including a weight loss drug and pays a dividend. There are two main risks, one being that insurance companies may not be able to pay for the weight loss drug until the pricing comes down. Also we don't really know what the side effects are and may not know for another five years. You can buy on weakness for exposure to the sector.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Also owns LLY and bought NVO for the same reasons: the obesity tailwind, but NVO is cheaper than LLY at 37x forward PE. This and LLY have 80-80% market share with tremendous growth and cash flow.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

She missed the trade, but would get in on a pullback. Certainly, there is a market (and growth) for obesity drugs like NVO's.

biotechnology / pharmaceutical
SELL
Novo-Nordisk

Big difference between a company and a stock. It's like buying a jacket for different price points of $1000, $300, or on sale for $150. You make an investment/purchase decision. 

LLY and NVO are great companies, but you have to look at how expensive they are. Quite expensive at around 50x earnings. Good growth rates. A reasonable multiple for a drug company is sub-20x, and these won't get there via discounted cashflow until next decade. That's a long way out.

He looks for things that have yet to be priced properly. He owns MRK.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Weight loss drugs go to a huge audience in the US. Have to take them for life. Helps indirectly with other conditions too. Lots of opportunity. Increased use means savings on health costs for government and insurance. Novo and LLY have an extensive lead on everyone else, which isn't going away. Yield is 1.5%.

(Analysts’ price target is $127.32)
biotechnology / pharmaceutical
COMMENT
Novo-Nordisk

A personal holding since 1995. Their weight-loss drug is the big news now. Remember that after this hype, we'll see if there are any long-term side effects (i.e. the stomach). It's an unproven drug, but could be fine. Meanwhile, they grow their dividend 12% annually. He took profits, because shares ran up so fast. Have the highest R&D to revenues among pharmas. A long-term hold.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Novo and Eli Lilly have both run up, but there's still more room to go, given the strong demand for their weight-loss drug. Insurers will probably pay for these drugs, because without them consumers couldn't afford them. Sure, others are developing their own drugs, but it's not easy. Pfizer just announced it's giving up.

biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Novo-Nordisk

You've seen the ads, heard the hype about NVO's Ozempic (and its related Wegovy). As noted above, weight-loss drugs are all the rage, and NVO has attracted as much hype as Taylor Swift's latest album. In mid-October, the Danish company raised full-year guidance in sales and operating profit for the third time this year. NZO expects sales growth of 32-38% up from the prior 27-33%, based on surging popularity for both its drugs in the U.S.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Global leader. Recently became Europe's most valuable company by market cap. Diabetes and obesity drugs. Weight loss drug data showing positive cardiac effects as well. Raised guidance to 38% sales growth this year, with operating profit near 46% on the top end. Obesity treatment projected to move from 1M to 48M users by 2030.

Share price above its moving averages, beating S&P, 25% earnings growth rate forecast. Yield is 0.89%.

(Analysts’ price target is $95.28)
biotechnology / pharmaceutical
PARTIAL SELL
Novo-Nordisk

The largest company in Scandinavia. There is and will be lots of competition in weight-loss drugs. NVO has made a fortune through this drug, but their margins will shrink over time as competitors come. If you own this already, take profits, but don't expect NVO to double again.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

Good job marketing Ozempic, taking the US and other countries by storm. Could be a $100B drug class for all participants. Significant weight loss, kidney and heart benefits. Always going to be side effects. Because of its runup, start with a 1/2 position, and then add on any weakness.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

He strongly disagrees with some analysts who say that the new weight-loss drugs won't move the needles of their company stocks. He expects huge demand for these drugs to battle diabetes, which would prevent many other diseases. He sees a lot of runway ahead for LLY and Novo Nordisk.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Good chart which is indicating momentum. Would recommend buying. 

biotechnology / pharmaceutical
Unspecified
Novo-Nordisk

It has had positive momentum but don't chase it. Two of its drugs are leaders in the space but we don't know the long term effects of these drugs. There are competing products being developed in the weight loss space.

biotechnology / pharmaceutical
Showing 1 to 15 of 127 entries

Novo-Nordisk(NVO-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 15

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 3

Total Signals / Votes : 18

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 18 stock analysts published opinions about NVO-N. 15 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

18 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2024-03-28, Novo-Nordisk (NVO-N) stock closed at a price of $129.85.